|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
DE69233528T2
(de)
|
1991-11-25 |
2006-03-16 |
Enzon, Inc. |
Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
|
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
|
PT1621554E
(pt)
|
1992-08-21 |
2009-07-13 |
Univ Bruxelles |
Imunoglobtainas desprovidas de cadeias leves
|
|
US6838254B1
(en)
|
1993-04-29 |
2005-01-04 |
Conopco, Inc. |
Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
|
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
|
FR2761994B1
(fr)
|
1997-04-11 |
1999-06-18 |
Centre Nat Rech Scient |
Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
|
|
DE60045319D1
(de)
|
1999-02-05 |
2011-01-13 |
Samsung Electronics Co Ltd |
Verfahren und Vorrichtung zum Wiederauffinden von Texturbildern
|
|
AU2006230099B2
(en)
|
2005-03-25 |
2012-04-19 |
Gitr, Inc. |
GITR binding molecules and uses therefor
|
|
CN101801413A
(zh)
|
2007-07-12 |
2010-08-11 |
托勒克斯股份有限公司 |
采用gitr结合分子的联合疗法
|
|
PT3023438T
(pt)
|
2009-09-03 |
2020-05-08 |
Merck Sharp & Dohme |
Anticorpos anti-gitr
|
|
EP2949670B1
(en)
|
2009-12-10 |
2019-02-27 |
F. Hoffmann-La Roche AG |
Antibodies binding preferentially human csf1r extracellular domain 4 and their use
|
|
KR101656548B1
(ko)
|
2010-03-05 |
2016-09-09 |
에프. 호프만-라 로슈 아게 |
인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
|
|
JP5989547B2
(ja)
|
2010-03-05 |
2016-09-07 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ヒトｃｓｆ−１ｒに対する抗体及びその使用
|
|
SMT201900074T1
(it)
|
2010-05-04 |
2019-02-28 |
Five Prime Therapeutics Inc |
Anticorpi che legano csf1r
|
|
SG10201912092VA
(en)
|
2010-09-09 |
2020-02-27 |
Pfizer |
4-1bb binding molecules
|
|
SI2699264T1
(en)
|
2011-04-20 |
2018-08-31 |
Medimmune Llc |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
EP2791174B1
(en)
|
2011-12-15 |
2018-02-28 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r and uses thereof
|
|
CN104093740B
(zh)
|
2012-02-06 |
2018-01-09 |
弗·哈夫曼-拉罗切有限公司 |
使用csf1r抑制剂的组合物和方法
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
KR20150018533A
(ko)
|
2012-05-11 |
2015-02-23 |
파이브 프라임 테라퓨틱스, 인크. |
콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
|
|
CN104684582A
(zh)
|
2012-08-31 |
2015-06-03 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
CR20170060A
(es)
|
2014-08-19 |
2017-04-18 |
Merck Sharp & Dohme |
Anticuerpos anti tigit
|
|
MY187045A
(en)
|
2014-12-23 |
2021-08-27 |
Bristol Myers Squibb Co |
Antibodies to tigit
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
PH12022553648A1
(en)
|
2015-09-25 |
2024-03-11 |
Genentech Inc |
Anti-tigit antibodies and methods of use
|
|
UA125062C2
(uk)
|
2015-10-01 |
2022-01-05 |
Потенза Терапеутікс, Інк. |
Анти-tigit антигензв'язуючі білки і способи їх застосування
|
|
SG11201805506YA
(en)
|
2016-01-08 |
2018-07-30 |
Arcus Biosciences Inc |
Modulators of 5'-nucleotidase, ecto and the use thereof
|
|
CN116514976A
(zh)
|
2016-03-04 |
2023-08-01 |
Jn生物科学有限责任公司 |
针对tigit的抗体
|
|
SG11201901077RA
(en)
|
2016-08-17 |
2019-03-28 |
Compugen Ltd |
Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
|
|
EP3518934A4
(en)
|
2016-10-03 |
2020-06-24 |
Arcus Biosciences, Inc. |
Inhibitors of adenosine 5'-nucleotidase
|
|
JP7150712B2
(ja)
|
2016-11-18 |
2022-10-11 |
アーカス バイオサイエンシズ インコーポレイティド |
Ｃｄ７３媒介免疫抑制の阻害剤
|
|
CA3044664C
(en)
|
2016-11-30 |
2022-11-22 |
Oncomed Pharmaceuticals, Inc. |
Methods for treatment of cancer comprising tigit-binding agents
|
|
CN109071656B
(zh)
|
2017-01-05 |
2021-05-18 |
璟尚生物制药公司 |
检查点调节物拮抗剂
|
|
TWI781136B
(zh)
|
2017-01-20 |
2022-10-21 |
美商阿克思生物科學有限公司 |
用於治療癌症相關病症之唑嘧啶
|
|
JP2020510422A
(ja)
|
2017-02-28 |
2020-04-09 |
シアトル ジェネティックス， インコーポレイテッド |
抗ｔｉｇｉｔ抗体
|
|
WO2018204661A1
(en)
|
2017-05-05 |
2018-11-08 |
Arcus Biosciences, Inc. |
Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
|
|
WO2018213377A1
(en)
|
2017-05-17 |
2018-11-22 |
Arcus Biosciences, Inc. |
Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
|
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
WO2019023504A1
(en)
|
2017-07-27 |
2019-01-31 |
Iteos Therapeutics Sa |
ANTI-TIGIT ANTIBODIES
|
|
TW201930358A
(zh)
|
2017-12-28 |
2019-08-01 |
大陸商南京傳奇生物科技有限公司 |
針對ｔｉｇｉｔ之單域抗體及其變異體
|
|
TWI816729B
(zh)
|
2017-12-30 |
2023-10-01 |
英屬開曼群島商百濟神州有限公司 |
抗tigit抗體及其作為治療和診斷的用途
|
|
CN110352200B
(zh)
|
2018-02-06 |
2020-12-11 |
天境生物科技(上海)有限公司 |
抗具有Ig和ITIM结构域的T细胞免疫受体(TIGIT)的抗体及其应用
|
|
MX2020008795A
(es)
|
2018-02-28 |
2020-10-08 |
Yuhan Corp |
Anti cuerpos anti tigit y usos de los mismos.
|
|
US12054500B2
(en)
|
2018-03-05 |
2024-08-06 |
Arcus Biosciences, Inc. |
Arginase inhibitors
|
|
BR112021001201A2
(pt)
|
2018-07-25 |
2021-04-27 |
Innovent Biologics (Suzhou) Co., Ltd. |
anticorpo anti-tigit e uso do mesmo
|
|
WO2020023846A1
(en)
|
2018-07-27 |
2020-01-30 |
Arcus Biosciences, Inc. |
Pyridone a2r antagonists
|
|
BR112021003156A2
(pt)
|
2018-08-23 |
2021-05-11 |
Seagen, Inc. |
composição, anticorpo que se liga ao tigit humano, formulação farmacêutica, polinucleotídeo isolado, vetor, célula hospedeira, métodos para a produção de um anticorpo que se liga ao tigit humano e de anticorpos afucosilados que se ligam a tigit e para o tratamento de um câncer, e, kit.
|
|
WO2020046813A1
(en)
|
2018-08-27 |
2020-03-05 |
Arcus Biosciences, Inc. |
Cd73 inhibitors
|
|
WO2020102646A2
(en)
|
2018-11-16 |
2020-05-22 |
Arcus Biosciences, Inc. |
Inhibitors of arg1 and/or arg2
|
|
CN111196852A
(zh)
|
2018-11-16 |
2020-05-26 |
四川科伦博泰生物医药股份有限公司 |
抗tigit抗体及其用途
|
|
KR20210113282A
(ko)
|
2019-01-07 |
2021-09-15 |
아이테오스 벨지움 에스에이 |
항-tigit 항체
|
|
TWI760751B
(zh)
|
2019-05-29 |
2022-04-11 |
美商美國禮來大藥廠 |
Tigit及pd-1/tigit-結合分子
|
|
CN114206332B
(zh)
|
2019-06-04 |
2024-08-23 |
艾库斯生物科学有限公司 |
2,3,5-三取代吡唑并[1,5-a]嘧啶化合物
|
|
KR102332847B1
(ko)
|
2019-06-13 |
2021-12-01 |
주식회사 녹십자 |
Tigit에 대한 항체 및 이의 용도
|
|
WO2021008523A1
(zh)
|
2019-07-15 |
2021-01-21 |
上海君实生物医药科技股份有限公司 |
抗tigit抗体及其应用
|
|
CN114206929B
(zh)
|
2019-09-03 |
2023-12-22 |
百奥泰生物制药股份有限公司 |
一种抗tigit免疫抑制剂及应用
|
|
US20230024438A1
(en)
|
2019-12-04 |
2023-01-26 |
Arcus Biosciences, Inc. |
Inhibitors of hif-2alpha
|
|
IL295569B1
(en)
|
2020-03-19 |
2026-04-01 |
Arcus Biosciences Inc |
Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2ALPHA
|
|
CN115916247B
(zh)
|
2020-04-19 |
2025-04-01 |
奥美药业有限公司 |
人tigit特异性单域抗体及其应用
|
|
CR20230476A
(es)
*
|
2021-04-30 |
2024-01-30 |
Medimmune Llc |
Proteínas de unión a pd-1 y tigit biespecíficas y usos de estas
|
|
CN114106182B
(zh)
*
|
2022-01-26 |
2022-05-17 |
中山康方生物医药有限公司 |
抗tigit的抗体及其用途
|